Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBT Margin (2022 - 2025)

Historic EBT Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 27.62%.

  • Axsome Therapeutics' EBT Margin rose 340400.0% to 27.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.05%, marking a year-over-year increase of 509200.0%. This contributed to the annual value of 74.45% for FY2024, which is 136100.0% up from last year.
  • Latest data reveals that Axsome Therapeutics reported EBT Margin of 27.62% as of Q3 2025, which was up 340400.0% from 32.61% recorded in Q2 2025.
  • Axsome Therapeutics' 5-year EBT Margin high stood at 9.13% for Q1 2023, and its period low was 469.82% during Q2 2022.
  • Over the past 4 years, Axsome Therapeutics' median EBT Margin value was 91.09% (recorded in 2024), while the average stood at 128.9%.
  • Per our database at Business Quant, Axsome Therapeutics' EBT Margin surged by 3246600bps in 2023 and then tumbled by -820100bps in 2024.
  • Over the past 4 years, Axsome Therapeutics' EBT Margin (Quarter) stood at 251.29% in 2022, then soared by 45bps to 138.37% in 2023, then soared by 54bps to 63.0% in 2024, then soared by 56bps to 27.62% in 2025.
  • Its EBT Margin stands at 27.62% for Q3 2025, versus 32.61% for Q2 2025 and 48.91% for Q1 2025.